Reply to open letter from Members of the European Parliament's letter on psychedelic-assisted therapies
EMA reply to a letter from Members of the European Parliament, Mr Agius Saliba, Ms Ries, Mr Duda, Mr Biedroń, Ms Cerdas and Ms Metz concerning psychedelic-assisted therapies
Response to the European Ombudsman concerning transparency and independence of EMA's work in supporting the development and evaluation of COVID-19 medicines
Reply to the European Ombudsman’s letter concerning transparency and independence of the work of the European Medicines Agency in supporting the development and evaluation of COVID-19 medicines
Response to the Institute for Quality and Efficiency in Health Care (IQWiG) and the Cochrane Collaboration on transparency of COVID-19-related activities
European Medicines Agency response to IQWIG on transparency of COVID-19 related activities
Reference Number: EMA/280976/2020Summary:
European Medicines Agency response to IQWIG on transparency of COVID-19 related activities